Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that has set its sights on the discovery, development, and commercialization of medications for treating serious central nervous system diseases. With its lead product candidate being the CNS-penetrant, soluble guanylate cyclase (sGC) stimulator called Zagociguat (CY6463), the company is currently in the midst of Phase IIa trials. This drug has potential for treating mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology, while also being tested for Phase 1 trials for the treatment of schizophrenia in adults. Additionally, Cyclerion Therapeutics, Inc. is developing the orally administered systemic sGC stimulator called Praliciguat, which is in Phase II studies for resistant hypertension and diabetic nephropathy. The company is also working on the orally administered vascular sGC stimulator, Olinciguat, which is in Phase II trials for sickle cell disease. Meanwhile, its CNS-targeted sGC stimulator, CY3018, is currently in the preclinical trial stage for treating neuropsychiatric diseases and disorders. Cyclerion Therapeutics, Inc. has a license agreement with Akebia Therapeutics, Inc. that includes the development, manufacture, medical affairs, and commercialization of pharmaceutical products, among other things. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics, Inc.'s ticker is CYCN
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Cyclerion Therapeutics, Inc.
It is https://www.cyclerion.com/
Cyclerion Therapeutics, Inc. is in the Healthcare sector
Cyclerion Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Cyclerion Therapeutics, Inc.'s industry peers: